Avellino’s test detects Covid-19 caused by a SARS-CoV-2. Credit: Fusion Medical Animation / Unsplash.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Avellino Lab USA has announced additional production shifts to scale up the manufacturing of the SARS-CoV-2/COVID-19 Test (AvellinoCoV2), its newly developed coronavirus (Covid-19) diagnostic.

This ultra-rapid genetic test helps clinicians diagnose Covid-19 caused by a SARS-CoV-2 virus infection by identifying and isolating the genetic markers as approved by the FDA and the CDC.

The test is considered to be in high demand among health systems, public health services and first-responders due its precision, speed and ability to detect the disease in asymptomatic patients.

To ramp up the production of AvellinoCoV2 test, company is expanding its operations into the genetic diagnostics lab as used for its AvaGen test that assesses the risk of developing keratoconus and the presence of corneal dystrophies.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

In addition, the company is temporarily suspending sequencing operations of its AvaGen genetic to meet the demand for its Covid-19-test.

Avellino Group chairman Gene Lee said: “We appreciate the support from eye care professionals who are now using the AvaGen genetic test to care for their corneal patients. We understand the breakthrough importance of the AvaGen test in treating patients with complex corneal conditions.

“Avellino will restart production of the AvaGen genetic test as soon as we have fulfilled our public health obligation surrounding the coronavirus pandemic.”

The validation process for AvellinoCoV2 was completed by the company earlier this month, according to the FDA issued guidance for laboratories developing Covid-19 tests.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact